|Cancer Research Wire|
Cancer research news for the public and news media. More stories can be found at the Newswise Cancer News Source.
In a surprise finding, researchers working with breast cancer cells purchased at the same time from the same cell bank discovered that the cells responded differently to chemicals, even though the researchers had not detected any difference when they tested them for authenticity at the time of purchase.
– Johns Hopkins Bloomberg School of Public Health
RO1 ES 020750 Embargo expired on 26-Jul-2016 at 05:00 ET
Personalized Medicine Leads to Better Outcomes; Phase 1 Study Results of Selinexor Combination Therapy for Multiple Myeloma Patients; and the Latest from ASCO Sessions in the Cancer News Source
/PRNewswire-USNewswire/ -- Physicians from Carolinas HealthCare System's Neurosciences Institute and Levine Cancer Institute are among the authors of a study that was accepted for publication by the Journal of the American Medical Association (JAMA). The study, released on July 26, 2016, shows that patients with the most common form of brain tumor can be treated in an effective and substantially less toxic way by omitting a widely used portion of radiation therapy. These results will allow tens of thousands of patients with brain tumors to experience a better quality of life while maintaining the same length of life.
– Carolinas Healthcare System
Journal of the American Medical Association
ROCHESTER, Minn. — Patients with three or fewer metastatic brain tumors who received treatment with stereotactic radiosurgery (SRS) had less cognitive deterioration three months after treatment than patients who received SRS combined with whole brain radiation therapy (WBRT). These findings are according to the results of a federally funded, Mayo Clinic-led, multi-institution research study published today in the Journal of the American Medical Association.
– Mayo Clinic
Adding a novel monoclonal antibody therapy called olaratumab to traditional chemotherapy increased median survival by nearly a year in patients with advanced sarcoma, according to a multicenter clinical trial led by researchers at Columbia University Medical Center and NewYork-Presbyterian.
– Columbia University Medical Center
Lancet online, June 9, 2016
VCU Health radiologist Jinxing Yu, M.D., uses magnetic resonance technology to diagnose with more than 90 percent success rate.
– VCU Massey Cancer Center
A laboratory study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes. The findings, reported by Andre Nussenzweig, Ph.D., and Shyam Sharan, Ph.D., at the National Cancer Institute (NCI), part of the National Institutes of Health, and colleagues, appeared July 21, 2016, in Nature.
– National Cancer Institute (NCI) at NIH
Nature, July 21, 2016. DOI: 10.1038/nature18325.
Researchers from Penn Medicine and other institutions found that treating metastatic thyroid cancer patients harboring a BRAF mutation with the targeted therapy vemurafenib —originally approved for melanoma patients with the mutation—showed promising anti-tumor activity in a third of patients. The results were published in this week’s Lancet Oncology.
– Perelman School of Medicine at the University of Pennsylvania
Lancet Oncology Embargo expired on 22-Jul-2016 at 18:30 ET
A new scientific study has characterized a checkpoint protein that allows certain brain tumor cells to avoid the immune system.
– Case Western Reserve University
Science, Jul-2016; F31CA196265; T32GM007250; T32AI089474; R01GM086550; R01CA154656; R21CA181875; R01HL111682; P30CA043703; UL1TR000439... Embargo expired on 22-Jul-2016 at 14:00 ET
Click here to go directly to the Physics News Source Sponsored by AIP.
A preliminary cell study at Saint Louis University finds combining curcumin, the active ingredient in spicy curry dishes, and silymarin, a component of milk thistle, inhibited the spread of colon cancer cells and increased cancer cell death.
– Saint Louis University Medical Center
In an effort to expand the number of cancer gene mutations that can be specifically targeted with personalized therapies, researchers at University of California San Diego School of Medicine and Moores Cancer Center looked for combinations of mutated genes and drugs that together kill cancer cells. The study, published July 21 in <i>Molecular Cell</i>, uncovered 172 new combinations that could form the basis for future cancer therapies.
– University of California San Diego Health Sciences
Molecular Cell Embargo expired on 21-Jul-2016 at 12:00 ET
Click here to go directly to the Cancer News Source
The American Society for Radiation Oncology (ASTRO) recently issued a new clinical practice statement, “Appropriate Customization of Radiation Therapy for Stage II and III Rectal Cancer: An ASTRO Clinical Practice Statement Using the RAND/UCLA Appropriateness Method.”
– American Society for Radiation Oncology (ASTRO)
Practical Radiation Oncology, MayJun-2016
UT Southwestern Medical Center researchers have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
– UT Southwestern Medical Center
A team of researchers from the University of Washington and the University of Trento in Italy unveiled an engineered protein that they designed to repress a specific cancer-promoting message within cells.
– University of Washington
Nature Chemical Biology; R01-GM103834
A new study published in the Journal of Cell Physiology describes how inflammation that characterizes fatty tissue is one of the main microenvironment actors responsible for promoting cancer. The authors also describe the involvement of steroid hormones and others factors produced by adipose tissue in breast cancer development.
– Sbarro Health Research Organization (SHRO)
Journal of Cellular Physiology
Research from Rutgers Cancer Institute of New Jersey and Rutgers School of Public Health shows no significant decline in indoor tanning rates among children under age 17 following a ban on such use in New Jersey enacted in 2013. The authors say it’s a finding that underscores a need for continued surveillance of this population and ongoing monitoring of indoor tanning facilities.
– Rutgers Cancer Institute of New Jersey
Journal of the American Academy of Dermatology, July 2016
MedStar Washington Hospital Center now offers Blue Light Cystoscopy with Cysview®, a new, FDA-approved technology used to pinpoint bladder tumors in patients with known or suspected bladder cancer.
– MedStar Washington Hospital Center
Researchers at the Mayo Clinic Center for Individualized Medicine have found a promising new way to monitor and treat recurrence of ovarian cancer — a hard-to-detect disease that claims many lives. New research from George Vasmatzis, Ph.D., of the Department of Laboratory Medicine and Pathology at Mayo Clinic, finds liquid biopsies from blood tests and DNA sequencing can detect a return of ovarian cancer long before a tumor reappears.
– Mayo Clinic
A new wonder compound developed by University of Bath scientists in collaboration with King's College London offers unprecedented protection against the harmful effects of UVA radiation in sunlight, which include photo-ageing, cell damage and cancer.
– University of Bath
Journal of Investigative Dermatology
A recent study by researchers at Johns Hopkins concludes that a substantial number of people with a history of the most frequent kind of nonmelanoma skin cancers still get sunburned at the same rate as those without previous history, probably because they are not using sun-protective methods the right way or in the right amounts.
– Johns Hopkins Medicine
Journal of the American Academy of Dermatology.; 1UL1TR001079; TL1 TR001078
A new scientific study has identified why colorectal cancer cells depend on a specific nutrient, and a way to starve them of it.
– Case Western Reserve University
Nature Communications, Jul-2016; R01CA196643; R21CA160060; R21CA181859; R01CA127590; P50CA150964; P30 CA043703; R37-DK060596; R01-DK053307...
The Food and Drug Administration has approved the first focused ultrasound device to treat essential tremor, the most common movement disorder, in patients who do not respond to medication. The scalpel-free approach has been pioneered by Jeff Elias, MD, at the University of Virginia School of Medicine, who led an international clinical trial that demonstrated the safety and effectiveness of the device.
– University of Virginia Health System
Dr. Steven Powell co-authors study in New England Journal of Medicine
– Sanford Health
New England Journal of Medicine, July 14, 2016
The number of new cases of metastatic prostate cancer climbed 72 percent in the past decade from 2004 to 2013, reports a new Northwestern Medicine study. The authors suspect the recent trend of fewer men being screened and more aggressive disease may be contributing to the rise. The largest increase in new cases was among men 55 to 69 years old, which rose 92 percent in the past decade. This rise is troubling because men in this age group are believed to benefit most from prostate cancer screening and early treatment.
– Northwestern University
Prostate Cancer and Prostatic Diseases; 5U01CA196390
The Radiology Leadership Institute® (RLI) named E. Stephen Amis Jr., MD, FACR, and Glendon G. Cox, MD, as this year’s Leadership Luminary Award recipients for their exceptional service to the medical specialty.
– American College of Radiology (ACR)
Integration of NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™) into NDSC CareSelect Imaging will provide access to evidence-based imaging recommendations adapted from the NCCN Guidelines®.
– National Comprehensive Cancer Network® (NCCN®)
Chicago (July 25, 2016): APHON submitted comments to the Department of Veterans Affairs (VA) supporting regulations to allow Advanced Practice Registered Nurses (APRNs) to practice to the full extent of their education, training, and certification. The pediatric hematology/oncology APRN’s scope of practice embraces the entire lifespan from infants to adults and the full trajectory from diagnosis to long-term survivorship/health surveillance of cancer or chronic blood disorders.
– Association of Pediatric Hematology/Oncology Nurses (APHON)
NantHealth, Inc., (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, today announced that it has partnered with the University of Utah in analyzing the entire genomic profiles of at least 1,000 individuals who have a history of rare and life-threatening diseases and conditions in their respective families. The landmark project will focus on researching the genetic causes of 25 conditions, including, breast, colon, ovarian, and prostate cancers, amyotrophic lateral sclerosis (ALS), chronic lymphocytic leukemia, autism, preterm birth, epilepsy, and other hereditary conditions. Genomic sequencing will be conducted with unique, comprehensive molecular tests offered by NantHealth.
– University of Utah Health Sciences
Advanced Instruments, Inc., a leader in laboratory instrumentation, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its GloCyte Automated Cell Counter System and GloCyte Low and High Level Controls.
– 2016 AACC Annual Meeting Press Program
– University of Chicago Medical Center